Ross Harris, Jennifer A Hall, A. Zaidi, N. Andrews, J. K. Dunbar, G. Dabrera
The New England journal of medicine, 2021
Vaccination against SARS-CoV-2 with either ChAdOx1 nCoV-19, produced by AstraZeneca, or BNT162b2, produced by Pfizer, has been shown to produce a robust antibody response (1,2), and is effective in both preventing cases and reducing the severity of COVID-19 in vaccinated individuals(3,4). While fewer cases will reduce disease burden, it is not yet clear whether these vaccinations will also reduce transmission in the minority who have been vaccinated but develop post-vaccination infection.
Cited by 50 publications.
Field of study: Medicine